evocatal GmbH, a Düsseldorf, Germany-based enzyme specialist, closed a €3.5m Series B funding round.
Backers included existing investors Roland Oetker, High-Tech Gründerfonds (HTGF), Sirius Seedfonds Düsseldorf (SSFD) and business angel Prof. Riesner and new investors Nrw.Bank and Lanxess.
The company intends to use the funds to extend its technology platform as well as its product portfolio.
Led by CEO Dr. Thorsten Eggert, evocatal develops and produces enzymes and fine chemicals for the chemicals and pharmaceuticals industries. Its biocatalysts are employed for the synthesis of pharmaceutical compounds and chemical intermediates, as well as in the production of consumer goods – for example in the manufacture and refinement of textiles, adhesives, detergents and cosmetics.
FinSMEs
27/06/2013
Related News
06/07/2010: Evocatal Closes €2M in Growth Financing